ES2822295T1 - Métodos y reactivos para el diagnóstico de la infección por SARS-CoV-2 - Google Patents
Métodos y reactivos para el diagnóstico de la infección por SARS-CoV-2 Download PDFInfo
- Publication number
- ES2822295T1 ES2822295T1 ES21158065T ES21158065T ES2822295T1 ES 2822295 T1 ES2822295 T1 ES 2822295T1 ES 21158065 T ES21158065 T ES 21158065T ES 21158065 T ES21158065 T ES 21158065T ES 2822295 T1 ES2822295 T1 ES 2822295T1
- Authority
- ES
- Spain
- Prior art keywords
- antibody
- infection
- sars
- cov
- iga
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
Abstract
Un método para diagnosticar una infección por SARS-CoV-2 que comprende la etapa de detectar la presencia o ausencia de un anticuerpo contra SEQ ID NO1, preferentemente anticuerpo de clase IgA, en una muestra de un sujeto.
Claims (15)
1. Un método para diagnosticar una infección por SARS-CoV-2 que comprende la etapa de detectar la presencia o ausencia de un anticuerpo contra SEQ ID NO1, preferentemente anticuerpo de clase IgA, en una muestra de un sujeto.
2. Un método para el diagnóstico diferencial de una infección por coronavirus, preferentemente para distinguir entre una infección por SARS-CoV; preferentemente por SARS-CoV-2; MERS, NL63, 229E, OC43 y HKU1, que comprende la etapa de detectar la presencia o ausencia de un anticuerpo contra SEQ ID NO1 en una muestra de un sujeto, preferentemente un anticuerpo de clase IgA y/o IgG, más preferentemente un anticuerpo de clase IgA.
3. El método según cualquiera de las reivindicaciones 1 o 2, en el que se detecta la presencia de un anticuerpo de clase IgG y/o IgM contra SEQ ID NO1 además de un anticuerpo de clase IgA contra SEQ ID NO1.
4. El método según cualquiera de las reivindicaciones 1 a 3, en el que la muestra es una muestra de sangre, preferentemente seleccionada del grupo que comprende sangre completa, suero o plasma.
5. El método según cualquiera de las reivindicaciones 1 a 4, en el que se detecta un anticuerpo de clase IgA contra SEQ ID NO1 usando un anticuerpo secundario marcado, preferentemente que se une a anticuerpos de clase IgA.
6. El método según cualquiera de las reivindicaciones 1 a 5, en el que el anticuerpo IgA se detecta usando un método seleccionado del grupo que comprende colorimetría, inmunofluorescencia, detección de actividad enzimática, quimioluminiscencia y radiactividad.
7. El método según cualquiera de las reivindicaciones 1 a 6, en el que la infección se detecta en una etapa temprana.
8. Un uso de un anticuerpo contra SEQ ID NO1, preferentemente anticuerpo de clase IgA, para diagnosticar una infección por SARS-CoV-2 o para el diagnóstico diferencial de una infección por coronavirus, preferentemente para distinguir entre una infección por SARS-CoV, preferentemente por SARS-CoV-2, MERS y NL63, 229E, OC43 y h Ku 1.
9. El uso según la reivindicación 8, en el que el uso es para el diagnóstico temprano de una infección por SARS-CoV-2.
10. Un kit que comprende un polipéptido que comprende SEQ ID NO1 o una variante del mismo, preferentemente recubierto con un vehículo útil para el diagnóstico y uno o más, preferentemente todos los reactivos del grupo que comprende un anticuerpo contra SEQ ID NO1, un tampón de lavado, un medio para detectar la presencia de anticuerpo contra SEQ ID NO1, preferentemente un anticuerpo de clase IgA, preferentemente un anticuerpo secundario que se une específicamente a anticuerpos de clase IgA, que comprende preferentemente un marcador detectable y un tampón de dilución.
11. El kit según la reivindicación 10, en el que el vehículo útil para el diagnóstico se selecciona del grupo que comprende una perla, preferentemente una perla paramagnética, una tira reactiva, una placa de microtitulación, una membrana, preferentemente del grupo que comprende transferencia western, transferencia de línea y transferencia de punto, un dispositivo de flujo lateral, una superficie de vidrio, un portaobjetos, una micromatriz y un biochip, y es preferentemente una placa de microtitulación.
12. El kit según la reivindicación 10 u 11, en el que el kit comprende dos o más, preferentemente tres o más calibradores.
13. El kit según la reivindicación 12, en el que cada calibrador es un anticuerpo recombinante que se une a SEQ ID NO1, que preferentemente es reconocido por un anticuerpo secundario que se une a anticuerpos de clase IgA.
14. Un uso de un polipéptido que comprende SEQ ID NO1 o una variante del mismo o un anticuerpo contra SEQ ID NO1, preferentemente un anticuerpo de clase IgA, para la fabricación de un kit de diagnóstico.
15. Un uso de un anticuerpo recombinante que se une a SEQ ID NO1 que preferentemente es reconocido por un anticuerpo secundario que se une a anticuerpos de clase IgA como calibrador para el diagnóstico temprano de una infección por SARS-CoV-2.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20158348 | 2020-02-19 | ||
| EP20158626.0A EP3715847A1 (en) | 2020-02-20 | 2020-02-20 | A method and reagents for the diagnosis of sars-cov-2 |
| EP20158821 | 2020-02-21 | ||
| DE202020003564 | 2020-08-20 | ||
| DE202020104982 | 2020-08-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2822295T1 true ES2822295T1 (es) | 2021-04-30 |
Family
ID=74591943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES21158065T Pending ES2822295T1 (es) | 2020-02-19 | 2021-02-19 | Métodos y reactivos para el diagnóstico de la infección por SARS-CoV-2 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210190797A1 (es) |
| EP (2) | EP3978927A3 (es) |
| JP (1) | JP7022969B2 (es) |
| KR (1) | KR102570713B1 (es) |
| CN (1) | CN113557431A (es) |
| AU (1) | AU2021223701B2 (es) |
| BR (1) | BR102021003012A2 (es) |
| CA (1) | CA3109607C (es) |
| DE (2) | DE202021100842U1 (es) |
| ES (1) | ES2822295T1 (es) |
| MX (1) | MX2022010234A (es) |
| RU (1) | RU2021134819A (es) |
| SG (1) | SG11202112544XA (es) |
| WO (1) | WO2021165448A1 (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112300251B (zh) * | 2020-02-24 | 2022-04-05 | 成都威斯克生物医药有限公司 | 抗SARS-CoV-2感染的蛋白及疫苗 |
| CN113087777B (zh) * | 2020-04-17 | 2023-05-05 | 成都威斯克生物医药有限公司 | 抗SARS-CoV-2感染的蛋白以及用该蛋白制备的疫苗 |
| US11644456B2 (en) * | 2020-04-28 | 2023-05-09 | Brandon Heeger | Rapid testing mechanism and method for respiratory viral pathogens |
| IT202000009625A1 (it) * | 2020-04-30 | 2021-10-30 | Takis S R L | Polinucleotidi codificanti antigeni di sars-cov-2 e relativo uso in campo medico come vaccini. |
| GB202006815D0 (en) * | 2020-05-07 | 2020-06-24 | Senseutics Ltd | Method |
| WO2021222988A1 (en) * | 2020-05-07 | 2021-11-11 | Griffith University | Cell entry-modulating agents and uses therefor |
| US11740240B2 (en) * | 2020-07-20 | 2023-08-29 | Bio-Rad Laboratories, Inc. | Immunoassay for SARS-CoV-2 neutralizing antibodies and materials therefor |
| CN114057846B (zh) * | 2020-08-07 | 2024-04-02 | 清华大学 | 一种预防新型冠状病毒感染covid-19的多肽、免疫原性偶联物及其用途 |
| CN112028978B (zh) * | 2020-09-07 | 2023-06-16 | 重庆医科大学 | 新冠病毒特异性cd8+t细胞表位肽及其应用 |
| US20220139567A1 (en) * | 2020-10-30 | 2022-05-05 | The Boeing Company | Methods for modeling infectious disease test performance as a function of specific, individual disease timelines |
| JP6976621B1 (ja) * | 2021-02-04 | 2021-12-08 | 株式会社Icst | 検査器具、検査キットおよび検査方法 |
| KR102426782B1 (ko) * | 2021-04-27 | 2022-07-28 | 국민대학교산학협력단 | SARS-CoV-2 RBD 항원 특이적 항체를 포함하는 진단용 조성물 또는 키트 |
| WO2022231320A1 (ko) * | 2021-04-27 | 2022-11-03 | 국민대학교산학협력단 | Sars-cov-2 s 단백질에 특이적으로 결합하는 항체 또는 그의 항원 결합 단편, 및 이들의 용도 |
| WO2023033363A1 (ko) * | 2021-09-06 | 2023-03-09 | 국민대학교산학협력단 | Sars-cov-2에 특이적으로 결합하는 이중특이적 항체 |
| CN113046370B (zh) * | 2021-05-31 | 2021-09-07 | 北京华芢生物技术有限公司 | 新型冠状病毒b．1．1．7英国突变株rbd的基因及其应用 |
| WO2022253260A1 (zh) * | 2021-06-01 | 2022-12-08 | 南京金斯瑞生物科技有限公司 | 新型冠状病毒及其突变株中和抗体的检测试剂盒 |
| GB202110391D0 (en) | 2021-07-19 | 2021-09-01 | Tissue Click Ltd | A detection kit and methods of detection of infectious agents |
| KR102602561B1 (ko) * | 2021-09-16 | 2023-11-17 | 한국공학대학교산학협력단 | 2019 신종 코로나바이러스 중화항체 검출용 측면유동분석 기반의 바이오센서 |
| CN113801963B (zh) * | 2021-09-17 | 2024-03-26 | 佛山科学技术学院 | 一种检测冠状病毒的引物探针组合、试剂盒及方法 |
| CN113929773B (zh) * | 2021-10-08 | 2023-02-28 | 国际遗传工程和生物技术中心泰州区域研究中心 | 一种抗SARS-CoV-2 S1-RBD单克隆抗体及其应用 |
| WO2023064631A1 (en) * | 2021-10-15 | 2023-04-20 | Chan Zuckerberg Biohub, Inc. | Engineering antigen binding to, and orientation on, adjuvants for enhanced humoral responses and immunofocusing |
| CN114075553B (zh) * | 2021-10-30 | 2023-10-03 | 西北工业大学 | 一种可用于新冠病毒中和抗体活性评价和作为核酸检测标准物的假病毒颗粒及其制备方法 |
| CN114014940B (zh) * | 2021-11-25 | 2022-11-15 | 华兰基因工程有限公司 | 一种2019-nCoV表面蛋白受体结合区融合蛋白制备方法 |
| CN114262694B (zh) * | 2021-12-06 | 2023-11-03 | 军事科学院军事医学研究院军事兽医研究所 | 以B型流感病毒为载体的SARS-CoV-2疫苗候选株及其构建方法和应用 |
| CN114315990B (zh) * | 2022-03-10 | 2022-05-27 | 北京康乐卫士生物技术股份有限公司 | 新型冠状病毒特异性单克隆抗体的制备及其应用 |
| CN114774412A (zh) * | 2022-03-15 | 2022-07-22 | 上海市东方医院（同济大学附属东方医院） | 新冠病毒vmiRNA前体序列、新冠病毒vmiRNA及应用 |
| CN114814216B (zh) * | 2022-06-30 | 2022-10-18 | 中国科学院基础医学与肿瘤研究所(筹) | 用于鉴别新冠核衣壳蛋白的核酸适体-抗体混合夹心法 |
| WO2024029523A1 (ja) * | 2022-08-02 | 2024-02-08 | 応用酵素医学研究所株式会社 | コロナウイルス感染症の評価項目を判断するための情報を提供する方法 |
| CN115951051B (zh) * | 2022-10-18 | 2024-01-12 | 北京卓诚惠生生物科技股份有限公司 | 一种高灵敏度新型冠状病毒抗原胶体金检测试剂盒及其制备方法 |
| CN117144063B (zh) * | 2023-09-15 | 2024-04-19 | 果然基因科技(山东)股份有限公司 | 一种12种呼吸道病原体荧光pcr熔解曲线试剂盒 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
| TW200512457A (en) * | 2003-06-10 | 2005-04-01 | Agency Science Tech & Res | Method of diagnosing SARS corona virus infection |
| CN1609617B (zh) * | 2003-09-29 | 2012-02-15 | 香港中文大学 | 诊断与预防严重急性呼吸道综合症（sars）的组合物和方法 |
| TWI303249B (en) * | 2004-01-09 | 2008-11-21 | Nat Health Research Institutes | Receptor binding polypeptides |
| CN101039955A (zh) * | 2004-06-04 | 2007-09-19 | 巴斯德研究院 | 与sars冠状病毒刺突蛋白相关的核酸、多肽、表达方法和免疫原性组合物 |
| CA2568838A1 (en) * | 2004-06-04 | 2005-12-15 | Institut Pasteur | Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein |
| US20060188519A1 (en) * | 2004-06-14 | 2006-08-24 | To Cheung | Peptides, antibodies, and methods for the diagnosis of SARS |
| GB0725239D0 (en) | 2007-12-24 | 2008-02-06 | Oncimmune Ltd | Calibrator for autoantibody assay |
| DE202011106093U1 (de) | 2011-09-24 | 2011-10-19 | Euroimmun Medizinische Labordiagnostika Ag | Kalibrationsstreifen für einen Immunoblot |
| KR20150064104A (ko) | 2012-09-23 | 2015-06-10 | 에라스무스 유니버시티 메디컬 센터 로테르담 | 사람 베타 코로나바이러스의 계통 c 및 이의 바이러스 수용체로서 n-말단 디펩티딜 펩티다아제의 확인 |
| CN113624977A (zh) * | 2020-05-09 | 2021-11-09 | 中国科学技术大学 | SARS-CoV-2感染诊断方法 |
| EP4105228A4 (en) * | 2020-05-11 | 2023-10-11 | Hengda Biomedical Technology Co., Ltd. | ANTIGENIC POLYPEPTIDE OF SARS-COV-2, RECOMBINANT ADENO-ASSOCIATED VIRUS THEREOF, AND USE IN VACCINE PREPARATION |
| CN111518175B (zh) * | 2020-05-11 | 2021-02-26 | 广东珩达生物医药科技有限公司 | Sars-cov-2抗原多肽及其重组腺相关病毒和在制备疫苗中的应用 |
-
2021
- 2021-02-18 BR BR102021003012A patent/BR102021003012A2/pt not_active Application Discontinuation
- 2021-02-19 RU RU2021134819A patent/RU2021134819A/ru unknown
- 2021-02-19 AU AU2021223701A patent/AU2021223701B2/en active Active
- 2021-02-19 EP EP22152107.3A patent/EP3978927A3/en not_active Withdrawn
- 2021-02-19 KR KR1020217042841A patent/KR102570713B1/ko active IP Right Grant
- 2021-02-19 WO PCT/EP2021/054113 patent/WO2021165448A1/en active Application Filing
- 2021-02-19 ES ES21158065T patent/ES2822295T1/es active Pending
- 2021-02-19 US US17/180,616 patent/US20210190797A1/en not_active Abandoned
- 2021-02-19 DE DE202021100842.3U patent/DE202021100842U1/de active Active
- 2021-02-19 JP JP2021025434A patent/JP7022969B2/ja active Active
- 2021-02-19 CA CA3109607A patent/CA3109607C/en active Active
- 2021-02-19 DE DE21158065.9T patent/DE21158065T1/de active Pending
- 2021-02-19 EP EP21158065.9A patent/EP3809137A1/en active Pending
- 2021-02-19 SG SG11202112544XA patent/SG11202112544XA/en unknown
- 2021-02-19 CN CN202180001126.9A patent/CN113557431A/zh active Pending
- 2021-02-19 MX MX2022010234A patent/MX2022010234A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202112544XA (en) | 2021-12-30 |
| MX2022010234A (es) | 2022-11-16 |
| JP7022969B2 (ja) | 2022-02-21 |
| EP3978927A3 (en) | 2022-06-22 |
| WO2021165448A1 (en) | 2021-08-26 |
| US20210190797A1 (en) | 2021-06-24 |
| AU2021223701A1 (en) | 2022-01-06 |
| EP3809137A1 (en) | 2021-04-21 |
| RU2021134819A (ru) | 2022-02-17 |
| BR102021003012A2 (pt) | 2021-11-30 |
| DE202021100842U1 (de) | 2021-08-17 |
| CA3109607C (en) | 2023-04-04 |
| EP3978927A2 (en) | 2022-04-06 |
| AU2021223701B2 (en) | 2022-05-19 |
| KR20220006125A (ko) | 2022-01-14 |
| CA3109607A1 (en) | 2021-05-20 |
| KR102570713B1 (ko) | 2023-08-25 |
| JP2021167805A (ja) | 2021-10-21 |
| DE21158065T1 (de) | 2021-06-10 |
| CN113557431A (zh) | 2021-10-26 |
| RU2021134819A3 (es) | 2022-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2822295T1 (es) | Métodos y reactivos para el diagnóstico de la infección por SARS-CoV-2 | |
| ES2788459T1 (es) | Método y reactivos para el diagnóstico de SARS-CoV-2 | |
| Nicol et al. | Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: Two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG Biotech) | |
| Li et al. | Immunologic testing for SARS-CoV-2 infection from the antigen perspective | |
| Osterman et al. | Comparison of four commercial, automated antigen tests to detect SARS-CoV-2 variants of concern | |
| US20150301035A1 (en) | Calibration strip for an immunoblot | |
| ES2930469T3 (es) | Ensayo para anticuerpos contra el virus jc | |
| Bailey et al. | Canadian society of clinical chemists (CSCC) interim consensus guidance for testing and reporting of SARS-CoV-2 serology | |
| CA2965189C (en) | A method for diagnosing primary biliary cirrhosis (pbc) using novel autoantigens | |
| Obeta et al. | Nigerian medical laboratory diagnosis of COVID-19; from grass to grace | |
| Parai et al. | Diagnostic accuracy comparison of three fully automated chemiluminescent immunoassay platforms for the detection of SARS-CoV-2 antibodies | |
| US20210356464A1 (en) | Serological assays for diagnosing or confirming covid-19 virus infections | |
| Horowitz et al. | To test or not to test? Laboratory support for the diagnosis of Lyme borreliosis | |
| ES2966766T3 (es) | Métodos para detectar la presencia de anticuerpos específicos para coronavirus en un sujeto | |
| US11703507B2 (en) | Immunoassay for SARS-CoV-2 antibodies | |
| JP2021172642A (ja) | ＳＡＲＳ−ＣｏＶ−２由来ヌクレオカプシド断片および該断片を用いて抗ＳＡＲＳ−ＣｏＶ−２抗体を検出する方法およびキット | |
| Wondimeneh et al. | Diagnostic Performance of SD Bioline Immunochromatography Test for the Detection of Rubella Specific IgM and Igg Antibodies in Resource Limited Settings | |
| Takahashi et al. | Assessment of antibody dynamics and neutralizing activity using serological assay after SARS-CoV-2 infection and vaccination | |
| Bakir et al. | Assessment of index value performance of enzyme immunoassay test in predicting the diagnosis of human brucellosis | |
| Goto | Performance evaluation of detecting adenovirus by using rapid diagnostic kits among Japanese people | |
| US20220034904A1 (en) | IMMUNOASSAY FOR SARS-CoV-2 ANTIBODIES | |
| Mohammed et al. | Sensitivity and Specificity of Gold Chromatography Immunoassays IgM/IgG Antibody Test for COVID-19: Review of the Current Literature | |
| WO2012127473A1 (en) | Method and kit for estimating human immunodeficiency virus (hiv) incidence | |
| Gededzha et al. | Evaluation Protocol for SARS-CoV-2 Serological Assays | |
| Sil et al. | AuNP Coupled Rapid Flow-Through Dot-Blot Immuno-Assay for COVID-19 (SARS-CoV-2) Explicit IgG Antibody Revelation |